Developer docs
API playgroundTry for free, no card

Search company profiles

CorFlow Therapeutics

Full company profile

uuid0000ubn

Namestring
CorFlow Therapeutics
Legal namestring
CorFlow Therapeutics AG
Websiteurl
corflow.com
Company typeenum
Private
Founded yearint
2016
Descriptiontext

CorFlow Therapeutics AG is a privately-held Swiss medical device company founded in 2016 and headquartered in Baar, Switzerland. The company is developing the CoFI (Controlled Flow Infusion) System, a proprietary integrated platform for real-time diagnosis and treatment of microvascular obstruction (MVO) in acute heart attack (STEMI) patients undergoing percutaneous coronary intervention (PCI). MVO is documented to occur in up to 60% of acute MI patients, cannot be detected during the index PCI under current standard of care, and is the most powerful prognostic indicator for adverse outcomes including heart failure re-hospitalization in up to 20% of treated patients.

The CoFI System combines a capital CoFI Console (with proprietary algorithm and GUI), a 6 French guide-compatible infusion-occlusion balloon CoFI Catheter that fits into the standard STEMI workflow using the existing 0.014" pressure wire, and single-use sterile CoFI Cassettes. A proprietary algorithm derives diagnostic parameters from real-time distal coronary back-pressure response to a dynamic infusion sequence, enabling physicians to detect MVO in the cath lab and to deliver therapeutic agents directly into the microcirculation. The platform received FDA Breakthrough Device Designation in October 2019. The first-in-human MOCA I study completed in 2024, the FDA approved the MOCA-II IDE Pivotal Trial in July 2025 (Phase 1 safety/performance met in 19 patients across 5 US and 3 European sites as of April 2026), and a parallel REVITALISE randomized controlled trial (≥250 patients) has been approved across the UK, France, Netherlands, and Spain.

The device remains investigational and CorFlow is pre-revenue. The intended commercial model is a capital-plus-consumable structure: CoFI Console placement at hospitals performing PCI, with recurring per-procedure revenue from CoFI Cassettes. Distribution will be direct enterprise sales to tertiary and quaternary cardiac centers through interventional cardiology KOL-driven adoption, leveraging existing trial sites as early reference accounts. The company has raised approximately €57M+ in cumulative funding, headlined by a €44M Series B in September 2024 led by Broadview Ventures and Panakes Partners, and operates with a senior team carrying deep Medtronic and interventional cardiology pedigree. Manufacturing is supported through BYTEC Medizintechnik GmbH.

Short descriptiontext

CorFlow Therapeutics AG is a Swiss medical device company developing the CoFI System, a proprietary integrated platform for real-time diagnosis and treatment of microvascular obstruction in STEMI heart attack patients undergoing PCI. Pre-revenue, the company is currently advancing pivotal trials across the US and Europe.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBaar, Switzerland
HQ citystring
Baar
HQ countrystring
Switzerland
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
interventional cardiology devices, microvascular obstruction diagnostics, coronary microcirculation assessment, PCI procedure medical devices, cardiac catheterization equipment
Industry3 codes
PRIMARYHLAKABAB
Interventional Cardiology (PCI/Structural Heart)
SECONDARYHLAHAFAI
Hemodynamic Monitoring & Cardiac Diagnostics (Cath Lab, FFR/IVUS/OCT)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
SECONDARYHLAHAIAH
Infusion Sets, Catheters & Pump Consumables
Healthcare & Life Sciences/Medical Devices & Diagnostics/Drug Delivery Devices (Injectors, Pumps, Inhalers)
NAICS code3 codes
  • Medical Equipment and Supplies Manufacturing3391
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
  • Measuring, Dispensing, and Other Pumping Equipment Manufacturing333914
SIC code3 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Electromedical & Electrotherapeutic Apparatus3845
  • Pumps & Pumping Equipment3561
Product category
Interventional Cardiology Medical Devices
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Medical Device and Consumable Sales
TypeHardware Sales
Description

Revenue from sale of CoFI Console (capital equipment) and single-use diagnostic cassettes. The consumables model provides recurring revenue from each procedure. Additional revenue potential from professional services for training and implementation support.

Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

CorFlow Therapeutics develops and manufactures the CoFI (Controlled Flow Infusion) System, a proprietary integrated medical device platform for real-time diagnosis and treatment of microvascular obstruction (MVO) in heart attack patients undergoing percutaneous coronary intervention (PCI). The system combines a capital console, a single-use sterile cassette, an infusion-occlusion balloon catheter, and a proprietary diagnostic algorithm that measures microvascular resistance to identify MVO during the index PCI procedure.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Reduction in heart failure re-hospitalizations in STEMI patients with MVO
Product overview1 text field

CorFlow Therapeutics offers the CoFI (Controlled Flow Infusion) System as its primary product platform. The system consists of three integrated components: the CoFI Console (capital equipment serving as an infusion pump with proprietary algorithm), the CoFI Catheter (infusion-occlusion balloon catheter), and the CoFI Cassette (single-use sterile cassette). The CoFI System is designed to diagnose microvascular obstruction (MVO) in real-time during PCI procedures and serve as a treatment platform for targeted intracoronary infusion of therapeutic agents. It is the first technology to enable physicians to measure microvascular function directly in the cath lab.

Product and service1 record
1CoFI System (Controlled Flow Infusion System)
CategoryInterventional Cardiology Medical Devices
Description

An integrated diagnostic and therapeutic medical device platform for interventional cardiologists and hospitals performing PCI procedures on STEMI heart attack patients. The CoFI System uses a proprietary algorithm to measure real-time distal coronary back-pressure response, enabling physicians to diagnose microvascular obstruction during the index procedure and to deliver controlled therapeutic infusions into the microcirculation. The platform integrates a CoFI Console (capital equipment with GUI and infusion pump), CoFI Cassette (single-use sterile disposable), and CoFI Catheter (6 Fr compatible infusion-occlusion balloon catheter).

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierManufacturing PartnerTypeTechnology or Integration
Description

Manufacturing partner for medical devices. BYTEC Medizintechnik GmbH specializes in development and manufacturing of medical devices and precision components for the healthcare industry.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

HeartFlow provides non-invasive FFR-CT analysis for assessing coronary artery disease, including microvascular dysfunction. Directly comparable as a coronary microvascular diagnostics platform targeting interventional cardiologists, though its approach is non-invasive imaging vs. CorFlow's catheter-based measurement.

TypeDirect peer
Description

OpSens manufactures the OptoWire, a pressure guidewire used for FFR and diastolic pressure ratio measurements during PCI procedures. Directly comparable as a coronary hemodynamic measurement technology used by interventional cardiologists during the same procedural workflow as CorFlow's CoFI System.

TypeDirect peer
Description

CathWorks developed the FFRangio system, an angio-based FFR computation technology for real-time coronary physiologic assessment during PCI. Comparable as a catheterization lab-based coronary hemodynamic diagnostic competing for the same interventional cardiology budget and workflow integration.

TypeDirect peer
Description

ACIST (owned by Bracco) provides the RXi system and FFR/IVUS technologies for hemodynamic assessment in the cath lab. Comparable as a provider of diagnostic consoles and catheters used by interventional cardiologists during PCI, with similar capital equipment plus consumables economics.

5Abbott
TypeBroad incumbent
Description

Abbott offers a broad interventional cardiology portfolio including OCT (Optis), IVUS, FFR (PressureWire), and coronary intervention devices. Relevant as a broad incumbent with established cath lab relationships and the resources to enter the MVO diagnostic space either organically or via acquisition.

TypeBroad incumbent
Description

Boston Scientific has a substantial interventional cardiology portfolio including IVUS, FFR (COMET system), and a broad coronary stent franchise. Comparable as a large incumbent with the R&D capacity, clinical trial infrastructure, and cath lab sales force that could either compete with or acquire emerging MVO diagnostics.

TypeBroad incumbent
Description

Medtronic is the global leader in interventional cardiology, with coronary stents, guidewires, and a broad portfolio across coronary and structural heart. Highly relevant as CorFlow CEO Paul Mead spent 18 years at Medtronic, and co-founder Prof. Rothman was Medtronic Coronary CMO, providing deep domain familiarity but also a potential future acquirer/competitor.

TypeBroad incumbent
Description

Philips acquired Volcano Corporation and offers IVUS, IFR, and FFR technologies for coronary physiologic assessment, alongside its broader image-guided therapy portfolio. Comparable as an incumbent with catheterization lab presence and the ability to bundle MVO diagnostics into existing hospital contracts.

TypeEmerging player
Description

Shockwave developed intravascular lithotripsy for calcium modification and was acquired by J&J in 2024 for $13B. Relevant as a precedent for how innovative interventional cardiology platforms achieve rapid commercial scale and exit value, demonstrating investor appetite in this category.

TypeEmerging player
Description

Penumbra develops catheter-based thrombectomy and vascular intervention technologies including coronary aspiration products. Comparable as an emerging medtech that scaled catheter-based interventional cardiology platforms from clinical stage to commercial success.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability1 record

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles14 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors12 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

CorFlow Therapeutics

Interventional Cardiology Medical Devicescorflow.com

CorFlow Therapeutics AG is a Swiss medical device company developing the CoFI System, a proprietary integrated platform for real-time diagnosis and treatment of microvascular obstruction in STEMI heart attack patients undergoing PCI. Pre-revenue, the company is currently advancing pivotal trials across the US and Europe.

What CorFlow Therapeutics does

CorFlow Therapeutics AG is a privately-held Swiss medical device company founded in 2016 and headquartered in Baar, Switzerland. The company is developing the CoFI (Controlled Flow Infusion) System, a proprietary integrated platform for real-time diagnosis and treatment of microvascular obstruction (MVO) in acute heart attack (STEMI) patients undergoing percutaneous coronary intervention (PCI). MVO is documented to occur in up to 60% of acute MI patients, cannot be detected during the index PCI under current standard of care, and is the most powerful prognostic indicator for adverse outcomes including heart failure re-hospitalization in up to 20% of treated patients.

The CoFI System combines a capital CoFI Console (with proprietary algorithm and GUI), a 6 French guide-compatible infusion-occlusion balloon CoFI Catheter that fits into the standard STEMI workflow using the existing 0.014" pressure wire, and single-use sterile CoFI Cassettes. A proprietary algorithm derives diagnostic parameters from real-time distal coronary back-pressure response to a dynamic infusion sequence, enabling physicians to detect MVO in the cath lab and to deliver therapeutic agents directly into the microcirculation. The platform received FDA Breakthrough Device Designation in October 2019. The first-in-human MOCA I study completed in 2024, the FDA approved the MOCA-II IDE Pivotal Trial in July 2025 (Phase 1 safety/performance met in 19 patients across 5 US and 3 European sites as of April 2026), and a parallel REVITALISE randomized controlled trial (≥250 patients) has been approved across the UK, France, Netherlands, and Spain.

The device remains investigational and CorFlow is pre-revenue. The intended commercial model is a capital-plus-consumable structure: CoFI Console placement at hospitals performing PCI, with recurring per-procedure revenue from CoFI Cassettes. Distribution will be direct enterprise sales to tertiary and quaternary cardiac centers through interventional cardiology KOL-driven adoption, leveraging existing trial sites as early reference accounts. The company has raised approximately €57M+ in cumulative funding, headlined by a €44M Series B in September 2024 led by Broadview Ventures and Panakes Partners, and operates with a senior team carrying deep Medtronic and interventional cardiology pedigree. Manufacturing is supported through BYTEC Medizintechnik GmbH.

CorFlow Therapeutics firmographics

Firmographics
Name
CorFlow Therapeutics
Legal name
CorFlow Therapeutics AG
Website
https://corflow.com
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
11–50 employees
Short description
CorFlow Therapeutics AG is a Swiss medical device company developing the CoFI System, a proprietary integrated platform for real-time diagnosis and treatment of microvascular obstruction in STEMI heart attack patients undergoing PCI. Pre-revenue, the company is currently advancing pivotal trials across the US and Europe.
Ownership category
akta.pro rank

CorFlow Therapeutics industry classification

Industry
Product category
Interventional Cardiology Medical Devices
NAICS
Medical Equipment and Supplies Manufacturing (3391), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Measuring, Dispensing, and Other Pumping Equipment Manufacturing (333914)
SIC
Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845), Pumps & Pumping Equipment (3561)
akta.pro industry
PRIMARYHLAKABAB
Interventional Cardiology (PCI/Structural Heart)
SECONDARYHLAHAFAI
Hemodynamic Monitoring & Cardiac Diagnostics (Cath Lab, FFR/IVUS/OCT)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
SECONDARYHLAHAIAH
Infusion Sets, Catheters & Pump Consumables
Healthcare & Life Sciences/Medical Devices & Diagnostics/Drug Delivery Devices (Injectors, Pumps, Inhalers)

Keywords

  • Interventional cardiology devices
  • Microvascular obstruction diagnostics
  • Coronary microcirculation assessment
  • PCI procedure medical devices
  • Cardiac catheterization equipment

Where CorFlow Therapeutics is headquartered

Location

Headquarters

HQ city
Baar
HQ country
Switzerland
HQ region
Europe

Offices1 record

Markets served

CorFlow Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. Medical Device and Consumable Sales: Revenue from sale of CoFI Console (capital equipment) and single-use diagnostic cassettes. The consumables model provides recurring revenue from each procedure. Additional revenue potential from professional services for training and implementation support.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

CorFlow Therapeutics product offering

Product offering

Core offering

CorFlow Therapeutics develops and manufactures the CoFI (Controlled Flow Infusion) System, a proprietary integrated medical device platform for real-time diagnosis and treatment of microvascular obstruction (MVO) in heart attack patients undergoing percutaneous coronary intervention (PCI). The system combines a capital console, a single-use sterile cassette, an infusion-occlusion balloon catheter, and a proprietary diagnostic algorithm that measures microvascular resistance to identify MVO during the index PCI procedure.

Product overview

CorFlow Therapeutics offers the CoFI (Controlled Flow Infusion) System as its primary product platform. The system consists of three integrated components: the CoFI Console (capital equipment serving as an infusion pump with proprietary algorithm), the CoFI Catheter (infusion-occlusion balloon catheter), and the CoFI Cassette (single-use sterile cassette). The CoFI System is designed to diagnose microvascular obstruction (MVO) in real-time during PCI procedures and serve as a treatment platform for targeted intracoronary infusion of therapeutic agents. It is the first technology to enable physicians to measure microvascular function directly in the cath lab.

Differentiator

Problem solved

Functional benefit

Products and services

  • CoFI System (Controlled Flow Infusion System) An integrated diagnostic and therapeutic medical device platform for interventional cardiologists and hospitals performing PCI procedures on STEMI heart attack patients. The CoFI System uses a proprietary algorithm to measure real-time distal coronary back-pressure response, enabling physicians to diagnose microvascular obstruction during the index procedure and to deliver controlled therapeutic infusions into the microcirculation. The platform integrates a CoFI Console (capital equipment with GUI and infusion pump), CoFI Cassette (single-use sterile disposable), and CoFI Catheter (6 Fr compatible infusion-occlusion balloon catheter).

Quantifiable outcome

  • Reduction in heart failure re-hospitalizations in STEMI patients with MVO

Companies that use CorFlow Therapeutics

Customer profile

Segments2 records

Ideal customer profiles2 records

CorFlow Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature3 records

CorFlow Therapeutics partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • BYTEC Medizintechnik GmbHmanufacturing partnerTechnology or IntegrationManufacturing partner for medical devices. BYTEC Medizintechnik GmbH specializes in development and manufacturing of medical devices and precision components for the healthcare industry.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

CorFlow Therapeutics competitors and assessment

Company assessment

Direct peers

  • HeartFlow: HeartFlow provides non-invasive FFR-CT analysis for assessing coronary artery disease, including microvascular dysfunction. Directly comparable as a coronary microvascular diagnostics platform targeting interventional cardiologists, though its approach is non-invasive imaging vs. CorFlow's catheter-based measurement.
  • OpSens: OpSens manufactures the OptoWire, a pressure guidewire used for FFR and diastolic pressure ratio measurements during PCI procedures. Directly comparable as a coronary hemodynamic measurement technology used by interventional cardiologists during the same procedural workflow as CorFlow's CoFI System.
  • CathWorks: CathWorks developed the FFRangio system, an angio-based FFR computation technology for real-time coronary physiologic assessment during PCI. Comparable as a catheterization lab-based coronary hemodynamic diagnostic competing for the same interventional cardiology budget and workflow integration.
  • ACIST Medical Systems: ACIST (owned by Bracco) provides the RXi system and FFR/IVUS technologies for hemodynamic assessment in the cath lab. Comparable as a provider of diagnostic consoles and catheters used by interventional cardiologists during PCI, with similar capital equipment plus consumables economics.

Broad incumbents

  • Abbott: Abbott offers a broad interventional cardiology portfolio including OCT (Optis), IVUS, FFR (PressureWire), and coronary intervention devices. Relevant as a broad incumbent with established cath lab relationships and the resources to enter the MVO diagnostic space either organically or via acquisition.
  • Boston Scientific: Boston Scientific has a substantial interventional cardiology portfolio including IVUS, FFR (COMET system), and a broad coronary stent franchise. Comparable as a large incumbent with the R&D capacity, clinical trial infrastructure, and cath lab sales force that could either compete with or acquire emerging MVO diagnostics.
  • Medtronic: Medtronic is the global leader in interventional cardiology, with coronary stents, guidewires, and a broad portfolio across coronary and structural heart. Highly relevant as CorFlow CEO Paul Mead spent 18 years at Medtronic, and co-founder Prof. Rothman was Medtronic Coronary CMO, providing deep domain familiarity but also a potential future acquirer/competitor.
  • Philips: Philips acquired Volcano Corporation and offers IVUS, IFR, and FFR technologies for coronary physiologic assessment, alongside its broader image-guided therapy portfolio. Comparable as an incumbent with catheterization lab presence and the ability to bundle MVO diagnostics into existing hospital contracts.

Emerging players

  • Shockwave Medical (J&J): Shockwave developed intravascular lithotripsy for calcium modification and was acquired by J&J in 2024 for $13B. Relevant as a precedent for how innovative interventional cardiology platforms achieve rapid commercial scale and exit value, demonstrating investor appetite in this category.
  • Penumbra: Penumbra develops catheter-based thrombectomy and vascular intervention technologies including coronary aspiration products. Comparable as an emerging medtech that scaled catheter-based interventional cardiology platforms from clinical stage to commercial success.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

CorFlow Therapeutics social profiles

Digital presence

CorFlow Therapeutics compliance and trust

Trust signal

Compliance1 record

CorFlow Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

CorFlow Therapeutics leadership team

Management profile

Number of profiles

Profiles14 records

CorFlow Therapeutics funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors12 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

CorFlow Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CorFlow Therapeutics

What does CorFlow Therapeutics do?

CorFlow Therapeutics develops and manufactures the CoFI (Controlled Flow Infusion) System, a proprietary integrated medical device platform for real-time diagnosis and treatment of microvascular obstruction (MVO) in heart attack patients undergoing percutaneous coronary intervention (PCI). The system combines a capital console, a single-use sterile cassette, an infusion-occlusion balloon catheter, and a proprietary diagnostic algorithm that measures microvascular resistance to identify MVO during the index PCI procedure.

Is CorFlow Therapeutics a public or private company?

CorFlow Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was CorFlow Therapeutics founded?

CorFlow Therapeutics was founded in 2016. It employs 11 to 50 people.

Where is CorFlow Therapeutics based?

CorFlow Therapeutics is headquartered in Baar, Switzerland, in the Europe region.

How does CorFlow Therapeutics make money?

One revenue line is on record: medical Device and Consumable Sales.

Who are CorFlow Therapeutics's main competitors?

Direct peers on record are HeartFlow, OpSens, CathWorks and ACIST Medical Systems. Broad incumbents are Abbott, Boston Scientific, Medtronic and Philips. Emerging players are Shockwave Medical (J&J) and Penumbra.

Does CorFlow Therapeutics have an API?

No public API is recorded for CorFlow Therapeutics.

What industry is CorFlow Therapeutics in?

CorFlow Therapeutics's product category is Interventional Cardiology Medical Devices. Its primary akta.pro industry code is HLAKABAB, Interventional Cardiology (PCI/Structural Heart), with a secondary code of HLAHAFAI, Hemodynamic Monitoring & Cardiac Diagnostics (Cath Lab, FFR/IVUS/OCT). Its NAICS code is 3391 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
startupticker.chSwiss medtechs hit milestones in cardiovascular careCorFlow Therapeutics advanced its FDA pivotal trial into Phase 2 and launched a parallel trial, while SQ Innovation received CE marking and EMA review acceptance for its subcutaneous device. CorFlow's Phase 1 met safety and performance goals, and SQ Innovation's product is approved in the US and now cleared in Europe.Financial PostCorFlow Therapeutics Announces Successful Completion of Phase 1 and First Patients Enrolled in Phase 2 of the MOCA II Pivotal Trial, Approval to Start the REVITALISE RCT in Europe, and Strengthening oCorFlow Therapeutics AG announced the successful completion of Phase 1 of its MOCA II FDA Pivotal Trial, with safety and performance goals met across 19 STEMI heart attack patients at 5 US and 3 European sites, triggering the start of Phase 2 enrollment. The company also received approval to begin the REVITALISE randomized controlled trial across the UK, France, Netherlands, and Spain, with at least 250 patients to be enrolled and results expected starting in 2027. Additionally, CorFlow strengthened its clinical leadership with the appointment of Dr. Rick Kuntz as Board Observer and senior scientific advisor and Dr. Pedro Eerdmans as Vice President Clinical.AETOSWireCorFlow Therapeutics AG Completes €44 Million Series B Financing to Support the Advancement of a Novel Diagnostic and Drug Delivery Platform for Microvascular Obstruction (MVO) in Heart Attack PatientsCorFlow Therapeutics raised €44 million in Series B funding to advance its CoFl system for diagnosing and treating microvascular obstruction in heart attack patients. The funds will support a pivotal US/EU trial and a randomized controlled therapy trial. The company aims to gain US market clearance for its diagnostic platform.AETOSWireCorFlow Therapeutics Appoints Chris O'Connell as Chairman of the Board of DirectorsCorFlow Therapeutics appointed Chris O'Connell as chairman, replacing Rick Geoffrion who remains on the board. The company is pursuing a Series B with two clinical trials and an FDA IDE trial. CorFlow's technology targets microvascular obstruction in heart attack patients.AETOSWireCorFlow Therapeutics Announces FDA Approval of the MOCA-II IDE Pivotal Trial to Validate a Novel Heart Attack Care TechnologyCorFlow Therapeutics announced FDA approval of its IDE for the MOCA-II pivotal trial, which will validate its CoFl system for diagnosing microvascular obstruction during heart attacks. The trial will enroll over 200 STEMI patients at U.S. and European sites, following the first-in-human MOCA-I trial in 2024.YahooCorFlow Therapeutics to begin pivotal trial of CoFl system for heart attack careCorFlow Therapeutics will begin a pivotal trial of its CoFl system for heart attack care, following FDA IDE approval. The trial will enroll over 200 STEMI subjects to compare CoFl's diagnostic readings with cardiac MRI. The company raised $48.5m in Series B funding in September 2024.AETOSWireCorFlow Therapeutics Announces Successful Completion of Phase 1 and First Patients Enrolled in Phase 2 of the MOCA II Pivotal Trial, Approval to Start the REVITALISE RCT in Europe, and Strengthening of Clinical LeadershipCorFlow Therapeutics completed Phase 1 of its MOCA II trial with 19 STEMI patients, meeting safety and performance goals. Phase 2 enrollment began, and the REVITALISE RCT is approved to start in the UK and other European countries. The company also appointed Dr. Rick Kuntz to the board and Dr. Pedro Eerdmans as VP Clinical.Business Wire BlogCorFlow Therapeutics Announces FDA Approval of the MOCA-II IDE Pivotal Trial to Validate a Novel Heart Attack Care TechnologyCorFlow Therapeutics announced FDA approval of its MOCA-II IDE pivotal trial to validate the CoFl system for diagnosing microvascular obstruction during heart attacks. The trial will enroll over 200 STEMI patients in the US and Europe, following the first-in-human MOCA-I trial in 2024. The technology aims to enable new treatments for the MVO patient population.Pulse 2.0CorFlow Therapeutics: €44 Million (Series B) Raised For Advancing Drug Delivery Platform Related To Microvascular Obstruction In Heart Attack PatientsCorFlow Therapeutics raised €44 million in Series B funding co-led by Broadview Ventures and Panakes Partners. The funds will support the MOCA II pivotal study in the US and Europe to validate its CoFl system for diagnosing microvascular obstruction in heart attack patients. The trial also funds an adaptive platform therapy study evaluating localized drug delivery.NextdigitalhealthCorFlow Secures $48.6M to Advance Novel Diagnostic & Drug Delivery PlatformCorFlow Therapeutics AG, a medical device company developing a diagnostic and drug delivery platform for microvascular obstruction after heart attacks, raised €44 million ($48.6 million) in a Series B round led by Panakes Partners and Broadview Ventures. The capital will fund the MOCA II pivotal study of its CoFITM System in Europe and the US, plus a study on adaptive platform therapy.